Mammaglobin 1: not only a breast‐specific and tumour‐specific marker, but also a hormone‐responsive endometrial protein

Claßen-Linke, I.; Moss, Sabine; Gröting, Katrin; Beier, Henning M.; Alfer, Joachim; Krusche, Claudia A.

doi:10.1111/j.1365-2559.2012.04290.x

Cited by 9 publications

(6 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SCGB2A1 and SCGB2A2 have poorly conserved sequences and are overexpressed in several gynecological cancers. Moreover, their tissue expression is under steroid regulation [56,57]. Although the actual biological functions of SCGBs are in general poorly understood, there is evidence of their anti-inflammatory and immunomodulatory effects [55]; in light of this, the current results suggest potentially important roles of SCGB2A family members during ovulation, a proposition that needs to be further investigated.…”

Section: Discussionmentioning

confidence: 73%

Transcriptome Profiling of Granulosa and Theca Cells During Dominant Follicle Development in the Horse1

Donadeu

Fahiminiya

Esteves

et al. 2014

Biology of Reproduction

View full text Add to dashboard Cite

Several aspects of equine ovarian physiology are unique among domestic species. Moreover, follicular growth patterns are very similar between horses and humans. This study aimed to characterize, for the first time, global gene expression profiles associated with growth and preovulatory (PO) maturation of equine dominant follicles. Granulosa cells (GCs) and theca interna cells (TCs) were harvested from follicles (n ¼ 5) at different stages of an ovulatory wave in mares corresponding to early dominance (ED; diameter !22 mm), late dominance (LD; !33 mm) and PO stage (34 h after administration of crude equine gonadotropins at LD stage), and separately analyzed on a horse gene expression microarray, followed by validation using quantitative PCR and immunoblotting/immunohistochemistry. Numbers of differentially expressed transcripts (DETs; !2-fold; P , 0.05) during the ED-LD and LD-PO transitions were 546 and 2419 in GCs and 5 and 582 in TCs. The most prominent change in GCs was the down-regulation of transcripts associated with cell division during both ED-LD and LD-PO. In addition, DET sets during LD-PO in GCs were enriched for genes involved in cell communication/adhesion, antioxidation/detoxification, immunity/inflammation, and cholesterol biosynthesis. In contrast, the largest change in TCs during the LD-PO transition was an upregulation of genes involved in immune activation, with other DET sets mapping to GPCR/cAMP signaling, lipid/amino acid metabolism, and cell proliferation/survival and differentiation.In conclusion, distinct expression profiles were identified between growing and PO follicles and, particularly, between GCs and TCs within each stage. Several DETs were identified that have not been associated with follicle development in other species.dominant follicle, equine, follicle development, gene expression, microarray

show abstract

Section: Discussionmentioning

confidence: 73%

Transcriptome Profiling of Granulosa and Theca Cells During Dominant Follicle Development in the Horse1

Donadeu

Fahiminiya

Esteves

et al. 2014

Biology of Reproduction

View full text Add to dashboard Cite

show abstract

“…However, numerous studies have shown that MGB1 is overexpressed in breast cancer cells and have suggested that MGB1 may be implicated in tumor aggressivity [6,12,25,26]. In support of a role for MGB1 in cancer aggressiveness, a growing number of studies have also shown a role for MGB1 in gynecologic malignancies [27][28][29][30].…”

Section: Discussionmentioning

confidence: 99%

Mammaglobin 1 promotes breast cancer malignancy and confers sensitivity to anticancer drugs

Picot

Guerrette

Beauregard

et al. 2015

Molecular Carcinogenesis

View full text Add to dashboard Cite

Mammaglobin 1 (MGB1), a member of the secretoglobin family, is expressed in mammary epithelial tissues and is overexpressed in most mammary carcinomas. Despite the extensive research correlating MGB1 expression profiles to breast cancer pathogenesis and disease outcome, the biological significance of MGB1 in cancer processes is still unclear. We have thus set out to conduct a functional evaluation of the molecular and cellular roles of MGB1 in breast cancer processes leading to disease progression. Using a series of breast cancer cell models with conditional MGB1 expression, we demonstrate that MGB1 promotes cancer cell malignant features. More specifically, loss of MGB1 expression resulted in a decrease of cell proliferation, soft agar spheroid formation, migration, and invasion capacities of breast cancer cells. Concomitantly, we also observed that MGB1 expression activates signaling pathways mediated by MAPK members (p38, JNK, and ERK), the focal adhesion kinase (FAK), matrix metalloproteinases (MMPs) and NFκB. Moreover, MGB1 regulates epithelial to mesenchymal (EMT) features and modulates Snail, Twist and ZEB1 expression levels. Interestingly, we also observed that expression of MGB1 confers breast cancer cell sensitivity to anticancer drug-induced apoptosis. Together, our results support a role for MGB1 in tumor malignancy in exchange for chemosensitivity. These findings provide one of the first descriptive overview of the molecular and cellular roles of MGB1 in breast cancer processes and may offer new insight to the development of therapeutic and prognostic strategies in breast cancer patients. © 2015 Wiley Periodicals, Inc.

show abstract

“…Studies by Classen-Linke et al (35) demonstrated that this expression is not restricted to breast tissue; it may also be detected in the endometrium where it changes in a hormone-dependent manner. To the best of our knowledge, this is the first study to measure the MGB1 RNA level in EC to understand its clinical significance.…”

Section: Discussionmentioning

confidence: 99%

A multimarker qPCR platform for the characterisation of endometrial cancer

et al. 2013

View full text Add to dashboard Cite

Abstract. The molecular background of endometrial cancer (EC) has not been fully elucidated. In the present study, we developed a quantitative PCR (qPCR) platform to examine the gene dosages of the potential molecular markers MGB1, TOP2A, ERBB1-4, MYC, CCND1, ESR1 and PI3K. The platform was applied in samples collected from 157 EC patients (stage I-IV) to verify its clinical utility and to examine the diagnostic and prognostic significance of the analysed biomarkers. The gene dosage pattern of the ERBB family and its downstream effectors PI3K and MYC showed particularly strong correlations with clinicopathological data. The ERBB PI3K/Akt pathway was upregulated in 31 (20%) of 156 cases. Activation of the ERBB PI3K/Akt pathway was positively correlated with a higher stage (p=0.001), higher grade (p=0.001), histological type II disease (p=0.0003) and metastases (p=0.02). The implemented hierarchical clustering revealed that cluster 2 was characterised by high copy numbers of the studied genes. Cluster 2 was associated with shorter overall survival (p=0.05). The platform was found to be a fast and simple method for direct analysis of the genes involved in uterine carcinogenesis, making it feasible for EC biology characterisation.

show abstract

Mammaglobin 1: not only a breast‐specific and tumour‐specific marker, but also a hormone‐responsive endometrial protein

Abstract: Our data show that MGB1 expression is not restricted to normal and malignant breast tissue. Besides its documented occurrence in endometriotic and malignant endometrial tissues, MGB1 is also expressed in normal human endometrium, and such expression is controlled by steroid hormones.

Cited by 9 publications

References 39 publications

Transcriptome Profiling of Granulosa and Theca Cells During Dominant Follicle Development in the Horse1

Transcriptome Profiling of Granulosa and Theca Cells During Dominant Follicle Development in the Horse1

Mammaglobin 1 promotes breast cancer malignancy and confers sensitivity to anticancer drugs

A multimarker qPCR platform for the characterisation of endometrial cancer

Contact Info

Product

Resources

About